GlassScriptPhysician profile
James T Siminski
NPI 1043206188
$8,689.65
in general payments reported to CMS, 2019-2025
34 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $1,435 · 2021: $1,817 · 2022: $1,272 · 2023: $1,809 · 2024: $462 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.60 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,970.27 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,470.50 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $1,452.88 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Insmed, INC. | $722.01 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $465.74 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $360.78 | 2019-2024 | Yupelri |
| Electromed, INC. | $243.48 | 2021-2023 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $238.87 | 2019-2025 | Uptravi |
| Jazz Pharmaceuticals INC. | $234.58 | 2019-2025 | |
| Inspire Medical Systems, INC. | $210.55 | 2023-2025 | Inspire |
| Grifols USA, LLC | $189.55 | 2021-2023 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $123.51 | 2022-2023 | |
| Philips North America LLC | $109.26 | 2019-2025 | Home Pi Undivided |
| Baxter Healthcare | $100.43 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $96.60 | 2020-2023 | Glassia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $93.72 | 2021-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $84.75 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $82.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.57 | 2021-2025 | Winrevair, Zerbaxa |
| Circassia INC. | $51.46 | 2019-2020 | |
| Viatris Specialty LLC | $42.38 | 2025 | Tobi Podhaler |
| Sunovion Pharmaceuticals INC. | $31.29 | 2019 | |
| Ambu INC. | $29.71 | 2025 | |
| Advanced Respiratory, INC | $26.70 | 2021 | |
| Shionogi INC | $26.06 | 2023 | Fetroja |
| Covis Pharma Gmbh | $23.53 | 2022 | |
| Genzyme Corporation | $22.53 | 2021 | |
| Ani Pharmaceuticals, INC. | $22.19 | 2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $20.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2021 | |
| Phadia US INC. | $19.08 | 2021 | |
| Lilly USA, LLC | $18.23 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $14.02 | 2023 | Acthar |
| 3b Medical, INC. | $13.95 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Siminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.